Introduction
Acute lymphoblastic leukemia (ALL) refers to a group of lymphoid disorders resulting from monoclonal proliferation and expansion of lymphoid blasts in the bone marrow, blood, and other organs. ALL is the most common childhood acute leukemia, accounting for about 80% of childhood leukemias, but it comprises only 20% of adult leukemias. ALL occurs at a rate of approximately 1 to 1.5 per 100,000 persons and exhibits a bimodal age distribution, with an early peak in children 4 to 5 years old (4 to 5 per 100,000), followed by a second peak at about 50 years of age (2 per 100,000) [1] . ALL is relatively uncommon in late childhood, adolescence, and young adulthood. Advances in ALL therapy have led to longterm survival rates exceeding 80% in children. Complete remission rates comparable to those in children can be achieved in adults by adapting pediatric ALL treatment strategies, but only about 30% to 40% of adults achieve long-term disease-free survival (DFS). Better understanding of the biology of ALL has led to changes of the pathologic classifi cation of the disease, emergence of new treatment options, and institution of risk-adapted therapies. New therapies are emerging based on the defi nition of specifi c cytogenetic-molecular abnormalities. However, long-term survival of adults is still inferior to that of children. Development of new drugs and agents tailored to subset-specifi c cytogenetic-molecular characteristics remains vital to therapeutic success in adult ALL.
Etiology
The etiology of ALL remains unknown. Chromosomal translocations occurring in utero during fetal hematopoiesis have been suggested as the primary cause of pediatric ALL, and postnatal genetic events are suggested as secondary contributors. A higher incidence of ALL is noted among monozygotic and dizygotic twins of patients with ALL, refl ecting possible genetic predisposition. Patients with trisomy 21, Klinefelter's syndrome, and inherited diseases with excessive chromosomal fragility (eg, Fanconi's anemia, Bloom syndrome, and ataxia-telangiectasia) have a higher risk of developing ALL [2] . Implications have also hinted at infectious etiologies. Associations between human T-cell lymphotrophic virus type 1 and adult T-cell leukemia/lymphoma, as well as HIV and lymphoproliferative disorders, have been established. In addition, associations with varicella and infl uenza viruses have been suggested.
Classifi cation
The French-American-British (FAB) Cooperative Group distinguishes three ALL groups (L1 to L3) based on morphologic criteria (cell size, cytoplasm, nucleoli, basophilia, vacuolation) [3] . The morphologic distinction between L1 and L2 has lost its prognostic signifi cance. L3 morphology is associated with mature B-cell ALL (Burkitt's leukemia). The World Health Organization (WHO) proposed new guidelines for the diagnosis of neoplastic diseases of hematopoietic and lymphoid tissues [4, 5] . In addition to lowering the blast count to greater than or equal to 20% as suffi cient for an ALL diagnosis, the morphologic distinction of L1, L2, and L3 morphologies is abandoned as no longer relevant. Both the FAB and WHO classifi cation systems continue to rely heavily on morphologic assessment. Identifi cation of the immunophenotype has become a major part of ALL diagnosis. Three broad groups can be distinguished: precursor Bcell ALL, mature B-cell ALL, and T-cell ALL.
Prognostic Factors
Several factors are considered when determining prognosis for adult patients with ALL. The presence of these risk factors increases the risk of relapse. Older age, high leukocyte count, immunophenotype other than T-cell, Philadelphia chromosome (Ph) positivity, and longer time to achieve initial complete response (CR) have all been associated with poor prognosis [6] . Other predictors of poor prognosis that have been suggested include poor performance status, presence of organomegaly, low platelet counts, low albumin levels, and elevated serum lactate dehydrogenase levels. In relapsed ALL, the presence of circulating peripheral blasts at the initiation of salvage treatment correlates with lower likelihood of response to chemotherapy and shorter survival [6] . In addition, short duration of complete response, increased bone marrow blasts, thrombocytopenia, and hypoalbuminemia adversely affect survival in relapsed patients [7••] .
Chemotherapy
The treatment of ALL remains among the most complex therapies of anticancer programs. Multiple drugs are molded into regimen-specifi c sequences of dose intensity and time intensity, with the goal of reconstituting normal hematopoiesis, preventing the emergence of resistant subclones, providing adequate prophylaxis of sanctuary sites (eg, central nervous system [CNS], testicles), and eliminating minimal residual disease (MRD) through postremission consolidation and maintenance [2] . Three distinct phases (induction, intensifi ed consolidation, and maintenance) are distinguished, with four components including CNS prophylaxis, which accompanies induction and consolidation.
The combination of vincristine, corticosteroids, and anthracyclines represents the backbone of ALL induction regimens. This combination achieves remission rates of 72% to 92%, with a median remission duration of about 18 months [8] . Dexamethasone is often substituted for prednisone because of better in vitro antileukemic activity and achievement of higher drug levels in the cerebro spinal fl uid (CSF) [9, 10] . Although L-asparaginase is an important agent in the treatment of pediatric ALL, its role in adult ALL is not well defi ned. Hematopoietic growth factors during induction accelerate recovery from myelosuppression and allow timely administration of dose-intense treatment regimens [11] .
Consolidation represents a repetition of a modifi ed induction schedule, rotational consolidation programs, or stem cell transplantation. Novel strategies try to emphasize subtype-oriented or risk-oriented approaches of consolidation programs.
The mainstays of maintenance therapy are daily 6-mercaptopurine, weekly methotrexate, and monthly pulses of vincristine and prednisone, given over 2 to 3 years. Extension of maintenance beyond 3 years is not benefi cial, nor is the omission or shortening of therapy [2] . No maintenance therapy is given in mature B-cell ALL, as these patients have a high cure rate with short-term, dose-intense regimens, and relapses beyond the fi rst year in remission are rare. The best maintenance for patients with Ph-positive ALL remains disputed but should incorporate effective BCR-ABL tyrosine kinase inhibitors.
Although CNS disease is found in less than 10% of patients at diagnosis, the rate can increase to as high as 50% to 75% at 1 year without CNS-directed therapy [12] [13] [14] . Standard prophylaxis for CNS malignancy can involve radiation therapy, systemic chemotherapy, intrathecal (IT) chemotherapy, or a combination of these. Cranial irradiation is associated with adverse effects such as secondary neoplasms, endocrinopathy, neurocognitive dysfunction, and neurotoxicity [15] [16] [17] . Combining early intensive systemic and IT chemotherapy can lower the CNS relapse rate in patients with ALL and may provide the opportunity to omit prophylactic cranial irradiation [18] . High-dose cytarabine (1-7.5 mg/m 2 ) and methotrexate (5-8 g/m 2 ) have the ability to penetrate the blood-brain barrier and can serve as CNS prophylaxis [19] [20] [21] [22] . However, it is diffi cult to maintain prolonged therapeutic concentrations of drug in the CSF using only systemic chemotherapy. Furthermore, systemic therapy is associated with widespread toxicities. High-dose cytarabine is associated with liver dysfunction, cerebellar dysfunction, mucositis, diarrhea, rash, and fever [23] . High-dose methotrexate is associated with renal dysfunction, transient hepatitis, mucositis, and (rarely) neurotoxicity [24] . The inclusion of IT chemotherapy in CNS prophylaxis protocols aims to improve the effi cacy of systemic therapy while circumventing its limitations. IT chemotherapy allows direct intra-CSF treatment and potentially sustained therapeutic drug concentration in the CSF [13] . Commonly used IT therapies include methotrexate, cytarabine, liposomal cytarabine, and thiotepa. In the absence of IT therapy, isolated CNS recurrence can account for 10% to 16% of relapses, warranting the inclusion of IT chemotherapy in CNS prophylactic regimens [24] . The effi cacy of high-
